Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Operating Expenses (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Operating Expenses for 4 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 7.48% to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.5 million, a 11.38% decrease, with the full-year FY2024 number at $10.0 million, up 102.92% from a year prior.
  • Operating Expenses was $2.3 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $1.9 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $4.2 million in Q2 2024 to a low of $27655.0 in Q3 2022.
  • A 4-year average of $1.6 million and a median of $1.7 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 5603.56% in 2023, then plummeted 55.91% in 2025.
  • 60 Degrees Pharmaceuticals' Operating Expenses stood at $513022.0 in 2022, then skyrocketed by 249.03% to $1.8 million in 2023, then rose by 23.93% to $2.2 million in 2024, then grew by 4.38% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Operating Expenses are $2.3 million (Q3 2025), $1.9 million (Q2 2025), and $2.1 million (Q1 2025).